Skyworks Solutions, Inc.

Skyworks Solutions’ recent 10-Q filing for the period ended April 3, 2026, presents a picture of slight revenue contraction alongside increased research and development expenditures. Item 7, Management’s Discussion and Analysis, shows net revenue for the three months ended April 3, 2026, at $943.7 million, a modest decrease from $953.2 million in the prior year’s comparable period. The six-month figures reflect a similar trend, with $1,979.1 million in net revenue compared to $2,021.7 million. Concurrently, research and development expenses rose to $212.4 million from $186.5 million, indicating ongoing investment despite the top-line shift.

The forensic scores, however, suggest a robust underlying financial condition. The Beneish M-Score, Beneish’s 1999 eight-ratio earnings-manipulation detector, registers at -3.0903, which is well below the -1.78 threshold for elevated manipulation risk. Altman’s Z″, Altman’s 1968 bankruptcy-distress index, stands at 4.85, comfortably above the 2.60 “safe” zone. The Piotroski F-Score, Piotroski’s 2000 nine-point fundamental strength scan, is 6.0 out of 9, indicating solid fundamental strength and not signaling weakness. Collectively, these metrics suggest the company’s accounting practices and financial stability are not currently a cause for concern.

Item 1A, Risk Factors, directs readers to the 2025 10-K for a comprehensive discussion, noting that factors discussed there “could materially affect our business, financial condition, or future results.” This common practice in quarterly reports means the current filing does not introduce new, specific risk factors but rather reiterates the continuity of previously identified risks. Additionally, Item 2, Unregistered Sales of Equity Securities and Use of Proceeds, details common stock repurchases during the quarter, indicating active capital management and a consistent approach to returning capital to shareholders through buyback programs.

This filing provides a snapshot of Skyworks Solutions’ recent operational performance and financial health indicators. It clearly outlines revenue trends, R&D investment, and ongoing capital allocation strategies. What it cannot convey, however, is the broader market context for semiconductor demand, the competitive landscape, or the efficacy of its R&D investments in future product cycles. Deciding whether the security is mispriced requires a deeper dive into these external factors, a read of the referenced 2025 10-K, and a view on the company’s long-term strategic positioning.